complement RCT data and prospective patient registries for the evaluation of contemporary practice including biomarkers used for diagnosis, treatment decisions and prognosis in the management of CML patients.

PCN148  
THE USE OF PERSONALISED MEDICINE IN CANCER TRIALS  
Covance Medical Consulting Ltd, Cambridge, Cambridge, UK  
OBJECTIVES: The consideration of subgroup analyses is an emerging topic in health care evaluation. With value-for-money being an important issue, alongside the question “is this therapy effective?”, another question becoming more relevant is “in whom is this therapy effective?” This issue is particularly relevant to the development of cancer treatments, which are often expensive and indicated in small patient populations. The use of personalised medicine is therefore expected to play a larger role in this disease area. The aim of this study was to investigate how the proportion of cancer trials taking personalised medicine into account has changed over time. A total of 2,190 interventional cancer trials that considered the use of personalised medicine, by using search terms including ‘diagnostic’, ‘prognostic’ and ‘biomarker’. Search results were de-duplicated, and the start dates of these trials were analysed and compared to those of all interventional cancer trials listed on ClinicalTrials.gov. RESULTS: In total, 2,190 cancer trials considered personalised medicine. The distribution of these was strongly skewed towards recent years, with only 57 of the trials identified having started before 2000. Across all cancer trials, 2.5% of those started before 2000 considered personalised medicine, whereas this percentage increased to 13.6% after that date. Interestingly, 20.6% of cancer trials commencing in 2010, compared to 17.0% of those in 2011, involved personalised medicine, indicating that there might be a slight decline in the investigation of personalised medicine recently. Trials considering individualised medicine were most often conducted in the United States or Europe, and in disease areas such as leukaemia, head and neck, and brain and prostate cancer. CONCLUSIONS: Personalised medicine has started to play a bigger role in cancer therapy development since the year 2000. With the current health care market focusing on value-for-money, however, it is surprising that only one-fifth of recent trials considered this issue.

PCN149  
TRANSFERABILITY OF PHARMACO ECONOMIC EVALUATIONS: CASE STUDY OF TRASTUZUMAB FOR EARLY BREAST CANCER  
Carwell C, McWilliams P, Lysseng-Williamson KA, Faulds D  
AstraZeneca, New York, USA  
OBJECTIVES: Using a simple method we determined the potential transferability of a previous economic evaluation on the cost effectiveness of adjuvant trastuzumab therapy for the treatment of HER2+ positive breast cancer in Canada (Skedgel et al, 2009) to five other countries (UK, US, Australia, Japan and Germany). METHODS: Based on data from a literature review, we firstly identified all possible transferability factors. From this we selected key transferability factors – those with values that differed across the countries or were factors that were shown to influence the cost-effectiveness ratio in sensitivity analysis in the Canadian reference study. We then considered the ease of transferability (ranging from very low to very high) for each of these potential factors from the Canadian study to the other countries. RESULTS: We identified seven potential key factors for transferability: cost discount rate, health outcomes discount rate, unit costs (particularly drug acquisition cost), sources used, treatment effectiveness (including duration of benefit) and measures used to determine utility values. Overall, potential transferability was highest for the UK, where treatment practice is similar to that in Canada and data on unit costs, resource use and discount rates are readily available. Because the author of the previous study did not use robust resource use data separately, however, transferability of the analysis was hindered. Transferability to Australia, Germany and the United States was of an intermediate level, while transferability to the Japanese setting was the lowest because treatment practice is likely to be different, and little cost of illness and utility data exist for that country. CONCLUSIONS: Several key factors need to be considered when evaluating whether a study is transferable to another setting. To enable the transferability of economic evaluations from one country to another, authors need to ensure that they report their economic data clearly and in sufficient detail.

PCN150  
DIRECT MEDICAL COSTS OF HEAD AND NECK CANCER IN THE UNITED STATES: AN ANALYSIS USING POOLED MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA  
Coghill D, Frick KD  
John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA  
OBJECTIVES: Pooling annual data together from the Medical Expenditure Panel Survey (MEPS) is legitimate way to produce average annual estimates based on “person-years” for any condition. AHRQ state that over 100 cases are required in order to do this. The objective of this study was to test the utility of using pooled MEPS data to calculate direct medical costs of head and neck cancer (HNC) using this data source. METHODS: MEPS data was pooled (2003-2008) and analyzed for respondents with HNC (CCS code = 11). Two different approaches were used. Consolidated year files and condition event files were used to calculate direct medical costs based on use and expenditures for persons with HNC (condition approach). Yearly event files were used to pool condition-event files to establish an attributable fraction approach. Both approaches inflated expenditure data to 2008 USD. RESULTS: A total of 120 respondents were identified to have a diagnosis of HNC when data was pooled. The condition approach estimated that the national yearly expenditures of HNC is in the order of $16.4bn with mean spend of $14.573 (SE = $2.227) per case per year. The attributable fraction approach estimated that expenditures for all events associated with HNC are significantly lower - $8.49bn with a mean of $4788 (SE = $1.057) per case per year. There were only 103 cases that had an event associated with the condition. Private payers accounted for most expenditure, though the proportion was slightly lower using the condition approach (46% vs. 56%). The analysis noted that attributable expenditures were driven by ambulatory visits where condition expenditures were driven by inpatient. CONCLUSIONS: Given the cost and importance of HNC, it is worthwhile to estimate the direct medical costs of a condition. This analysis illustrates that for rare cases, such as HNC, that both approaches offer insight into characterizing a condition. Subsequently, a range for cost estimates can be determined using this data source.

PCN151  
DESIGNING CASE REPORT FORMS FOR ECONOMIC EVALUATION ALONGSIDE CLINICAL TRIALS: A CASE STUDY USING AN INTERACTIVE DATA ANALYSIS TOOL TO STREAMLINE DATA COLLECTION  
Foley K  
Thomson Reuters, Cambridge, MA, USA  
OBJECTIVES: Determining which economic and health resource utilization data points to collect in clinical trials requires a balance between comprehensiveness and data collection burden. Cost and time constraints necessitate that only the most critical economic variables be collected. Our objective was to test the utility of a new tool for determining the most frequent types and timing of healthcare utilization among cancer patients in a quick and low cost manner. METHODS: We used an online interactive data analysis tool, MarketScan®Treatment Pathways, to explore the most frequent adverse events (AE) and their related healthcare utilization patterns in a sample of small-cell cancer patients (NSCLC). Patients with at least 30 days of follow-up from 7 different days after their first cancer diagnosis were included. The subset of patients with a diagnosis for metastatic cancer following their NSCLC diagnosis who received at least one oral or injectable chemotherapy treatment were analyzed. RESULTS: 5,433 patients with metastatic NSCLC were identified, of whom 2,906 received at least one oral or injectable treatment. 80% of experienced at least one AE serious enough to require healthcare intervention. The median and mean days to the first AE were 20 and 51.5 days from the time of the first treatment. The most common AEs were anemia (51.2%), gastrointestinal events (34.4%), fatigue (26.1%), and neutropenia (24.2%). Of those with anemia, 36% reported dizziness or gynecomastia and alpha and of those with neutropenia, 77% received pegfilgrastim or filgrastim. Additional patient clinical and treatment characteristics were described for the 30 days following each AE. Total analysis time for this project was under 3 hours. CONCLUSIONS: Treatment Pathways answered critical questions for the design of economic endpoint data collection for a new cancer trial in just a few hours.

PCN153  
A TRIAL FOR EVALUATING BREAST CANCER TUMOR MARKER USE IMPACT: A VALUE OF RESEARCH ANALYSIS  
Tharani R, Blough DK, Barlow W, Henry NL, Grant J, Ramsey S, Veenstra DL  
Thrastar, Inc, Seattle, WA, USA, 1University of Michigan Medical School, Ann Arbor, MI, USA, 2Seattle Cancer Care Alliance, Seattle, WA, USA, 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 4University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA  
OBJECTIVES: To assess the societal value of a prospective randomized clinical trial (RCT) for breast tumor marker testing in routine follow-up of high-risk, stage II-III breast cancer survivors. METHODS:MEPS is often used to assess the benefits of reducing uncertainty of using breast cancer tumor markers. We developed a decision-analytic model of biomarker testing in addition to standard surveillance at follow-up appointments every 3-6 months for five years. Expected value of sample information (EVI) was assessed over a range of trial sizes and assumptions. RESULTS: The overall value of research for an RCT involving 9000 women was $166 million (EVS1). The value of improved information characterizing the survival impact of tumor markers was $81 million, quality-of-life $38 million, and test performance $95 million. CONCLUSIONS: Despite not being recommended by clinical guidelines, the tumor markers carcinoembryonic antigen (CEA) and CA15-3 and CA 27.29 are used by some clinicians to screen for increased risk of breast cancer recurrence. Although additional research may be warranted to evaluate the benefits and risks of breast cancer tumor marker tests, clinical trials would likely need to involve thousands of women and would take many years to complete. Our analysis indicates that substantial societal value may be gained by conducting a clinical trial evaluating the use of breast cancer tumor markers. The most important aspects of the trial in our analysis were information gained on survival improvements as well as quality-of-life parameters associated with testing and testing sensitivity and specificity. Our analysis indicates that smaller randomized clinical trials, as well as adding quality of life instruments to existing trials, retrospective, and observational trials can also generate valuable and relevant information.

PCN154  
CHALLENGES POSED BY PATIENT CROSSOVER FOR COST-EFFECTIVENESS ANALYSIS OF ONCOLOGY PRODUCTS: A CASE STUDY IN METASTATIC PANCREATIC CANCER  
Grina DT, Brown ST, Attard CL, Duong MT  
Cornerstone Research Group, Burlington, ON, Canada
OBJECTIVES: Clinical trials of oncology products often allow crossover of control patients to the treatment arm following disease progression. This can underestimate a product’s overall survival (OS) and affects challenges for cost-effectiveness analyses compared. METHODS: A lifetime model compared the cost-effectiveness of a hypothetical pancreatic cancer therapy (CRG001) to gemcitabine. Gemcitabine survival data were derived from published studies. A hazard ratio of 0.55 was assumed for CRG001 with an S$5000 every 2 weeks for a maximum of 12 cycles and gemcitabine cost S$200 every 1 week for a maximum of 24 cycles. Analyzes were conducted: 1) 0%; 2) 50%; and 3) 85% crossover of gemcitabine patients to CRG001. Patient crossover occurred at the time of disease progression. Crossover patients received the CRG001 hazard ratio. Patients progressing in CRG001 were assumed to receive palliative care. A secondary analysis allowed 50% crossover but excluded second-line costs of CRG001. Costs and outcomes were discounted at 5%. RESULTS: The cost per QALY gained for CRG001 compared with current care was S$81,352 with 50% crossover but excluded second-line costs of CRG001. Costs and outcomes were discounted at 5%. RESULTS: The cost per QALY gained for CRG001 compared with current care was S$181,352 with no cross-over, S$69,292 with 50% crossover and S$40,992 with 85% crossover. In the analysis when cross-over of gemcitabine patients to CRG001 was excluded, the second-line costs of CRG001 was S$140,118. CONCLUSIONS: The first three analyses illustrate that CRG001 cost-effectiveness decreases with increasing cross-over of gemcitabine patients, if the costs of CRG001 for crossover patients are included. In our experience, however, reimbursement agencies often require a primary analysis that excludes second-line costs of the study drug for patients that cross-over. This analysis yields a high ratio that could lead to a negative reimbursement decision. In this case, where second-line CRG001 costs are excluded, adjustment of OS for crossover of gemcitabine alone patients is required. Overall, consideration must be given to the extent and potential impact of cross-over when conducting cost-effectiveness analysis of new oncology products.

PCN155

PATIENT BENEFIT-RISK PREFERENCES FOR ADVANCED RECURRENT CARCINOMA TREATMENTS: RESULTS FROM A CONJOINT ANALYSIS STUDY


OBJECTIVES: To quantify patients’ benefit-risk preferences for benefits, toxicities, and serious adverse events of advanced RCC treatments. METHODS: Adult residents of the United States, with a self-reported diagnosis of RCC completed a web-enabled choice-format conjoint survey consisting of a series of 10 treatment-choice questions, and a pair of hypothetical RCC medication profiles. Each profile had different attributes, i.e., efficacy (FFS), tolerability (fatigue, stomach problems, mouth sores, hand-foot syndrome (HFS)), patient compliance (formulation, price, number of doses), and mode of administration. Treatment-choice questions were based on a predetermined experimental design with known statistical properties. Random-parameters logit was used to estimate relative preference weights for each attribute level, mean relative importance weights, and calculate risk tolerance for each adverse event for different improvements in FFS. RESULTS: A total of 272 respondents completed the survey. A 7-month improvement in FFS was the most important attribute. Remaining attributes were ranked in decreasing order of importance: eliminating severe fatigue (7.0; 95% CI: 4.6–9.4), eliminating severe stomach problems (7.0; 95% CI: 4.7–9.3), eliminating a 2% liver-failure risk (6.1; 95% CI: 4.0–8.2), eliminating severe mouth sores (5.7; 95% CI: 3.7–7.7), eliminating severe HFS (4.5; 95% CI: 2.7–6.4), eliminating a 2% lung-damage risk (4.1; 95% CI: 2.5–5.8), and switching from infusion once a week to 1 pill once a day (2.5, 95% CI: 1.4–3.6). To increase FFS by 1 month (baseline: 3 – 4 months), participants accepted a maximum level of lung damage risk of 1.0% (95% CI: 0.8% – 1.4%) and liver failure risk of 0.7% (95% CI: 0.4% – 1.0%). A 7-month improvement in FFS was 2 times as important as eliminating severe HFS and a 2.0% risk of lung damage (P < 0.05). CONCLUSIONS: FFS was the most important outcome for RCC patients while severe fatigue and severe stomach problems were rated as the most troublesome toxicities.

PCN156

DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED QUESTIONNAIRE TO ASSESS THE QUALITY OF LIFE OUTCOMES OF INDIAN BREAST CANCER PATIENTS

Deshpande P, Chittharkhoppal Am, Bommareddy LS, Mallasamy S

METHODS: The FACT-Th18 questionnaire is needed to be used in larger population. For better results the instrument is needed to be used in larger population.

PN157

VALUATION AND LINGUISTIC VALIDATION OF THE FACT-TH18 FOR USE WITH CANCER PATIENTS WITH THROMBOCYTOPENIA WORLDWIDE

Arnold D, Dhar J, Parks-Vernizzi E, Debb S

OBJECTIVES: Translation of patient reported outcomes (PRO) measures is an essential component of the research methodology required when preparing for multinational clinical trials. One such measure is the Functional Assessment of Cancer Therapy-Thrombocytopenia 18 questionnaire (FACT–TH18), which evaluates the quality of life (QOL) of cancer patients with thrombocytopenia. This study set out to linguistically validate the FACT–TH18 scale for use in China, Greece, Hong Kong, Japan, India, Israel, Korea, Taiwan and Thailand. The combined sample consisted of 160 patients (81 males/79 females) diagnosed with thrombocytopenia. Patient mean age was 46 years, and at the time of administration, 146 patients were receiving treatment. The sample consisted of patients who speak Arabic, Chinese, Traditional, Chinese-Simplified, Greek, Gujarati, Hebrew, Hindi, Japanese, Korean, Malayalam, Marathi, Punjabi, Tamil, Thai and Tamil. The FACT–TH18 was translated based on the established FACIT methodology. Patients completed the respective translated questionnaire corresponding to their primary language and then participated in a cognitive interview to determine if there were any problems with the translations or item content. Quantitative analyses were performed on the combined sample and participant comments were analyzed qualitatively in order to confirm the validity of the translations. RESULTS: During the translation process terms such as “petechiae”, “pinpoint bruising” and “platelet transfusions” proved difficult to translate. The FACT–TH18 translations proved relevant to patients from a wide range of countries and were well understood. Very few of the required adjusted items translated as a result of the linguistic checking.

CONCLUSIONS: The FACT–TH18 demonstrated linguistic validity across all 16 languages. The translations are considered acceptable for PRO assessment in international research and clinical trials.

PCN158

PROJECTING STATE LEVEL ESTIMATES FOR RARE DISEASE USING CENSUS DATA AND HEALTH CARE CLAIMS DATABASE

Doo S, Victor T, Gomez A

OBJECTIVES: Estimating prevalence rates for rare medical conditions such as renal cell carcinoma (RCC) at state level by age and sex is difficult due to the paucity of available data resources. Available information may be fragmented because of a lack of national level surveillance. The use of commercial medical claim data alone is insufficient for estimation because the use of these data tends to result in biased estimates due to business practices of managed care organization. METHODS: Inversion Data Mart and the US census data were used to address this problem. The study inclusion criteria for defining RCC patients was age of 18 years or older without prior history of HIV/AIDS, HBV, or HVC diagnoses and had at least 2 outpatient medical claim with an associated ICD9 code of 189. First, we estimated prevalence rates for the medical conditions by state, age, and sex using ICD9 codes from the commerical data (2002-2010). Then, reanalyzed using post-stratification produced prevalence rates that take important health care related factors into account in the estimation process. We recommend the use of this combined approach for the estimation of prevalence rates of rare disease conditions and procedures.

INFECT–Clinical Outcomes Studies

PN1

OUTCOMES ASSOCIATED WITH SEVERE COMORBIDITIES IN HOSPITALIZED CASES OF HIV/AIDS

Villa L, Skrepek G

University of Arizona, Tucson, AZ, USA, 2University of Arizona, College of Pharmacy, Tucson, AZ, USA

OBJECTIVES: To assess economic and clinical characteristics of severe comorbidities during inpatient hospitalizations in persons with HIV/AIDS. METHODS: The Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (H-CUP) Nationwide Inpatient Sample (NS) was used in this retrospective database study spanning 2005-2009. Inpatient cases of HIV/AIDS among persons 18 years of age or older were used as inclusion criteria. Key clinical characteristics were analyzed including discharge status, length of stay, death, cancer, heart failure, pulmonary circulation disorders, coagulopathies, fluid/electrolyte disorders, and wasting syndromes/weight loss. Outcomes of inpatient mortality and hospital charges were assessed via multivariate logistic and gamma regression, respectively. The impact of controlling for patient demographics, clinical characteristics, payer, and lengths of stay. RESULTS: There were 1,227,718 overall inpatient cases of HIV/AIDS from 2005-2009 in the United States, averaging 44.8 (+10.7) years of age, 6.7 (+9.0) days for length of stay, and inpatient charges of $36,004 (+59,303). Mortality occurred in 41,609 cases, constituting 3.4% of all HIV/AIDS hospitalizations and averaging 47.0 (+11.1) years of age, 13.4 (+17.4) days for length of stay, and inpatient charges of $104,558 (+136,254). Fluid/electrolyte disorders